Clinical trials: Multiple Sclerosis Lesion
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Multiple Sclerosis
Ultra-high-field Brain MRI in Multiple Sclerosis
The MRI scan is one of the most important tools for diagnosing multiple sclerosis (MS) and for monitoring disease progression and medication effects.
- Trial name
- ULTIMS (NCT05718947)
- Testing
- Brain MRI (3T, 7T, 9.4T)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Zuyderland Medisch Centrum
Multiple Sclerosis)
Combined Sensitivity and Specificity of Cortical Lesions and Central Vein Sign for MS Diagnosis and Differential Diagnosis
This study investigates the specificity/sensitivity of the combined presence of cortical lesions (CLs)/leuco-cortical lesions (LCLs) and central veins sign (CVs) for multiple sclerosis (MS) diagnosis and differential diagnosis.
- Trial name
- NCT04369898
- Testing
- Image analysis/ Central vein detection, Image analysis/ Automatic cortical lesion detection
- Where
- Switzerland
- Volunteers
- 1,051 people
- Sponsor
- University Hospital, Basel, Switzerland
Optic Neuritis
Linking Optic Nerve MRI and the Retinal Axonal Loss After Optic Neuritis
This study evaluates the length of optic nerve lesion on 3D-DIR sequence as an imaging biomarker predictive of retinal axonal loss and visual disability, 12 months after the occurence of a first clinical episode of optic neuritis.
- Trial name
- IRMANO (NCT03651362)
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Lille
Angiofibroma of Face, Tuberous Sclerosis
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric…
- Trial name
- NCT03363763
- Testing
- Sirolimus 0.2%, Sirolimus 0.4%
- Where
- 8 sites in United States, China
- Volunteers
- 24 people
- Sponsor
- Aucta Pharmaceuticals, Inc
Multiple Sclerosis
Simultaneous T2-FLAIR and T1 Brain MRI With ENRAGED FLAIR in Multiple Sclerosis
This study will evaluate a new brain MRI technique called ENRAGED FLAIR in patients with multiple sclerosis. MRI is central in the diagnosis and follow-up of multiple sclerosis because it can show inflammatory lesions in the…
- Trial name
- ENRAGED FLAIR (NCT07687693)
- Testing
- ENRAGED FLAIR MRI
- Where
- Sweden
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Region Stockholm
Multiple Sclerosis
Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist
The investigators are conducting a magnetic resonance imaging (MRI) study comparing two MRI contrast agents in people with clinically isolated syndrome and relapsing remitting multiple sclerosis (MS).
- Trial name
- NCT01836055
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Multiple Sclerosis
Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
To compare two commonly used MS medications, IFN β-1a subcutaneous three times per week (Rebif) and oral twice daily dimethyl fumarate (Tecfidera), on mean number of new or enlarging T2 lesions at 6 months in adults with…
- Trial name
- NCT02419638
- Testing
- Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
- Where
- United States
- Sponsor
- Brigham and Women's Hospital
Primary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
- Trial name
- ORATORIO-Cort (NCT05974839)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- State University of New York at Buffalo
Hypertension, Heart Failure
LSFG-SKIN, Laser Speckle Flowgraphy
The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or…
- Conditions
- Hypertension, Heart Failure, Vascular Ischemia, Burns
- Trial name
- NCT03660618
- Testing
- laser speckle flowgraphy
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Randy Kardon
Multiple Sclerosis
Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Background: Multiple sclerosis (MS) is a disease of the central nervous system (CNS). People who have MS may have lesions that form on parts of the CNS, such as the brain. Some of these lesions may be inflamed for a long time.
- Trial name
- NCT04025554
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Relapsing Multiple Sclerosis
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
- Trial name
- ASCLEPIOS I (NCT02792218)
- Testing
- Ofatumumab subcutaneous injection, Teriflunomide capsule
- Where
- 166 sites in United States, Argentina and 27 more
- Volunteers
- 930 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy, Focal Cortical Dysplasia
Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery
Refractory epilepsy, meaning epilepsy that no longer responds to medication, is a common neurosurgical indication in children. In such cases, surgery is the treatment of choice.
- Conditions
- Epilepsy, Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly
- Trial name
- NCT04344626
- Testing
- Intra-operative brain tonometry
- Where
- 2 sites in United States, Canada
- Sponsor
- University of California, Los Angeles
Clinically Isolated Syndrome, Multiple Sclerosis
Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion
This is a multicentric and prospective study for the validation of a diagnostic method in multiple sclerosis. Our hypothesis is that there is a characteristic profile of tears that can be recognized in order to help in the…
- Trial name
- POLAR (NCT02043964)
- Testing
- tears and cerebrospinal fluid sampling
- Where
- 15 sites in France
- Volunteers
- 165 people
- Sponsor
- Lille Catholic University
Demyelinating Diseases, Demyelination; Corpus Callosum
Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with acute inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments.
- Conditions
- Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive
- Trial name
- ReINFORCE (NCT06065670)
- Testing
- Clemastine Fumarate
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05156281
- Testing
- Remibrutinib, Teriflunomide
- Where
- 223 sites in United States, Argentina and 25 more
- Volunteers
- 1,007 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
This study will: Explore whether GA decreases inflammation more on the 3T optimized protocol when compared to the 1.5T standard protocol.
- Trial name
- NCT00937157
- Testing
- Copaxone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University at Buffalo
Multiple Sclerosis, Clinically Isolated Syndrome
AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
The definition of the most 'at-risk' population within highly susceptible groups would provide an opportunity for preemptive therapeutics.
- Trial name
- ARMS (NCT00617383)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Sclerosis
3D Phase Sensitive Inversion Recuperation MRI to Detect and Characterize Multiple Sclerosis Spinal Cord Lesions
This study aims to assess the interest of 3D Phase Sensitive Inversion Recuperation (PSIR)sequence in the MRI detection of spinal cord lesion.
- Trial name
- ESPOIR (NCT02896647)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.